Third Harmonic Bio, Inc. (THRD)

NASDAQ: THRD · Real-Time Price · USD
11.25
-0.58 (-4.90%)
Dec 12, 2024, 4:00 PM EST - Market closed
-4.90%
Market Cap 506.91M
Revenue (ttm) n/a
Net Income (ttm) -39.20M
Shares Out 45.06M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 303,450
Open 11.56
Previous Close 11.83
Day's Range 10.97 - 11.64
52-Week Range 8.08 - 16.94
Beta 2.66
Analysts Strong Buy
Price Target 20.33 (+80.71%)
Earnings Date Nov 7, 2024

About THRD

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc.... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2022
Employees 30
Stock Exchange NASDAQ
Ticker Symbol THRD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for THRD stock is "Strong Buy." The 12-month stock price forecast is $20.33, which is an increase of 80.71% from the latest price.

Price Target
$20.33
(80.71% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference

SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respirat...

17 days ago - GlobeNewsWire

Third Harmonic Bio to Participate in Upcoming Investor Conferences in November

SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respirat...

5 weeks ago - GlobeNewsWire

Third Harmonic Bio Announces Third Quarter 2024 Financial Results

THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million  as of September 30, 2024 SAN FRANC...

5 weeks ago - GlobeNewsWire

Third Harmonic Bio to Participate in Upcoming Investor Conferences in September

SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respira...

3 months ago - GlobeNewsWire

Third Harmonic Bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respirat...

3 months ago - GlobeNewsWire

Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $255.3 million  as of June 3...

4 months ago - GlobeNewsWire

Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respirato...

7 months ago - GlobeNewsWire

Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update

U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway,  with results expected during 1H'25 Strengthened leadership tea...

7 months ago - GlobeNewsWire

Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today a...

9 months ago - GlobeNewsWire

Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results

U.S. IND filed for THB335 with anticipated clinical trial start during 2Q'24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO, Mar...

9 months ago - GlobeNewsWire

Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference

SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today an...

10 months ago - GlobeNewsWire

Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update

Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy

1 year ago - GlobeNewsWire

Third Harmonic Bio Announces Third Quarter 2023 Financial Results

On track to file a U.S. Investigational New Drug (IND) application for THB335 and  initiate clinical studies in 1H'24

1 year ago - GlobeNewsWire

Third Harmonic Bio Announces Leadership Changes

SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today an...

1 year ago - GlobeNewsWire

Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference

SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today an...

1 year ago - GlobeNewsWire

Third Harmonic Bio Announces Second Quarter 2023 Financial Results

Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distrib...

1 year ago - GlobeNewsWire

Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335

THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution and physicochemical profile

1 year ago - GlobeNewsWire

Third Harmonic Bio Announces First Quarter 2023 Financial Results

Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated ...

1 year ago - GlobeNewsWire

Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results

Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated ...

1 year ago - GlobeNewsWire

Top 5 Health Care Stocks That May Rally - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: AMGNAZNPFE
2 years ago - Benzinga

5 Cheapest Health Care Stocks You Should Think About

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: ABBVFATETECH
2 years ago - Benzinga

5 Cheapest Health Care Stocks You Should Think About - Baxter Intl (NYSE:BAX), Cutera (NASDAQ:CUTR)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: CUTRBAXVERA
2 years ago - Benzinga

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: FATEIPSCVERA
2 years ago - Benzinga

Third Harmonic's stock falls 75% after discontinuing clinical trial

Shares of Third Harmonic Bio Inc. tumbled 75% in premarket trading on Thursday after the company said it discontinued the Phase 1b study of its treatment for chronic inducible urticaria, a common infl...

2 years ago - Market Watch

Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria

-- Company decision follows observation of asymptomatic liver transaminitis in two subjects enrolled in first dose cohort of 200mg BID

2 years ago - GlobeNewsWire